Incyte Corporation (BMV:INCY)

Market Cap	283.72B
Revenue (ttm)	86.46B
Net Income (ttm)	16.42B
Shares Out	n/a
EPS (ttm)	82.38
PE Ratio	17.28
Forward PE	12.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80
Average Volume	1,373
Open	1,306.32
Previous Close	1,180.69
Day's Range	1,306.32 - 1,306.32
52-Week Range	1,156.16 - 1,486.00
Beta	n/a
RSI	n/a
Earnings Date	Jul 29, 2025

About PetIQ

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.